Laurence J. (Larry) Hyman focuses his practice on biotechnology patenting, strategic planning and counseling, technology licensing, intellectual property due diligence, patent portfolio evaluations, and portfolio management. Mr. Hyman also advises clients on compliance with reporting requirements for research conducted under federal funding. Mr. Hyman has represented a wide variety of clients, including the U.S. Government, academic institutions, start-up and medium sized biotechnology and drug discovery companies, venture capital groups, and pharmaceutical companies. In addition to his practice at Hyman IP Law, Mr. Hyman is of counsel to the law firm canady + lortz LLP.
Mr. Hyman's patent and licensing work has encompassed biologics (particularly antibody- and cytokine-based targeted therapeutics), protein chemistry, biochemistry, molecular biology, RNA interference, immunology, human and animal vaccines, plant biology, agricultural methods and compositions, transgenic plants and bacteria, biofuels, personalized medicine, enzymology, nanotechnology, stem cells, food coatings and processing, drug administration, high throughput screening, water purification, imaging methods, radiation administration, and microfluidic and medical devices.
Mr. Hyman serves as a reviewer of grant applications on therapeutics for the University of California, San Francisco, Clinical and Translational Science Institute ("CTSI"), and was recognized by CTSI in 2015 as an "Outstanding Advisor" for his contributions to CTSI's Catalyst Awards Program. Mr. Hyman also serves as a reviewer of applicants to the California Life Sciences Association's "FAST" Advisory Program for start-ups and as a consultant on biotechnology patent matters to the Gerson Lehrman Group expert network. Mr. Hyman was recognized as a 2011 "Top Patent Prosecutor for Pharmaceuticals/Biotechnology" by the patent analytics website PatentBuddy.com.
Before founding HYMAN IP LAW, Mr. Hyman practiced for over 11 years at Townsend and Townsend and Crew, LLP, a national, IP-focused firm (now part of Kilpatrick Townsend & Stockton LLP), where he was a partner in the Biotechnology and Chemistry Practice Group. Prior to joining Townsend, Mr. Hyman was with the National Institutes of Health's Office of Technology Transfer, where he served as the lead patent advisor for the General Medicine Workgroup.
HYMAN IP LAW
555 Califorina Street, Suite 4925
San Francisco, CA 94104-1717